Carvedilol has emerged as the preferred β-blocker for treating portal hypertension. However, there is still a debate in dosing regimen, with a potential lower bioavailability in once-daily regimens. The aim of this study is to assess the acute effects of carvedilol posology in patients with clinically significant portal hypertension (CSPH), as a surrogate marker of bioavailability.

中文翻译：

---

卡维地洛剂量学时机对临床显着门静脉高压的影响：来自弹性成像测量的见解。

卡维地洛已成为治疗门脉高压的首选β受体阻滞剂。然而，剂量方案仍存在争议，每日一次的方案生物利用度可能较低。本研究的目的是评估卡维地洛剂量学对具有临床意义的门脉高压（CSPH）患者的急性影响，作为生物利用度的替代标志物。